Overview of nanoparticle albumin-bound paclitaxel in metastatic breast cancer

摘要

Breast cancer remains the most commonly diagnosed cancer in women in the USA and is estimated to be responsible for 14% of cancer-related deaths in 2012. Taxane chemotherapy agents are a mainstay of treatment for metastatic breast cancer, but unfortunately, significant toxicities can limit their use. Nanoparticle albumin-bound (nab)-paditaxel is a formulation of paclitaxel that is bound to an albumin nanoparticle. This allows for improved solubility as well as higher plasma clearance and volume distribution without the hypersensitivity reactions and myelosuppression of standard Cremophor?-based paclitaxel. This article will review nanoparticle albumin-bound paclitaxel in the treatment of metastatic breast cancer.